Canadian application, no grantCanada
Isoxazole derivatives for the treatment of irritable bowel syndrome
CA 2100399 A1 · Owner: Eli Lilly And Company · Inventors: Schaus, John Mehnert; Gidda, Jaswant Singh
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Provided is a method of treating Irritable Bowel Syndrome (IBS) using a series of isoxazole derivatives that have both 5-HTlA agonist and Ml muscarinic activities and, formulations suitable therefor.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 13, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 13, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 13, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJuly 13, 1993
GrantedNo grant recorded
Term endedJuly 13, 2013
Patent numberCA 2100399 A1
Classification (IPC)A61K31/42
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.